Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
about
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial SarcomaADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
P2860
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@ast
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@en
type
label
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@ast
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@en
prefLabel
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@ast
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@en
P2093
P2860
P50
P1433
P1476
Quisinostat, bortezomib, and d ...... for relapsed multiple myeloma.
@en
P2093
Ann Forslund
Charles Phelps
Christopher Doty
Cyrille Touzeau
Julie Badamo-Dotzis
Lotfi Benboubker
Martine Delain
Nele Fourneau
Peter Hellemans
P2860
P304
P356
10.3109/10428194.2015.1117611
P577
2016-01-12T00:00:00Z